Wave Life Sciences (WVE) Stock Forecast, Price Target & Predictions
WVE Stock Forecast
Wave Life Sciences stock forecast is as follows: an average price target of $14.00 (represents a 172.90% upside from WVE’s last price of $5.13) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
WVE Price Target
The average price target for Wave Life Sciences (WVE) is $14.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $17.00 to $11.00. This represents a potential 172.90% upside from WVE's last price of $5.13.
WVE Analyst Ratings
According to 4 Wall Street analysts, Wave Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for WVE stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Wave Life Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 25, 2024 | Joon Leen | Truist Financial | $17.00 | $4.77 | 256.39% | 231.38% |
| May 15, 2024 | Tiago Fauth | Wells Fargo | $11.00 | $5.84 | 88.36% | 114.42% |
The latest Wave Life Sciences stock forecast, released on Jun 25, 2024 by Joon Leen from Truist Financial, set a price target of $17.00, which represents a 256.39% increase from the stock price at the time of the forecast ($4.77), and a 231.38% increase from WVE last price ($5.13).
Wave Life Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $17.00 | $14.00 |
| Last Closing Price | $5.13 | $5.13 | $5.13 |
| Upside/Downside | -100.00% | 231.38% | 172.90% |
In the current month, the average price target of Wave Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Wave Life Sciences's last price of $5.13. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | William Blair | - | Outperform | Initialise |
| Aug 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jun 26, 2024 | Mizuho Securities | Underperform | Underperform | Hold |
| Jun 26, 2024 | Wells Fargo | Buy | Buy | Hold |
| May 15, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| May 15, 2024 | RBC Capital | Underperform | Underperform | Hold |
| May 15, 2024 | Wells Fargo | - | Overweight | Initialise |
| Dec 19, 2023 | Leerink Partners | - | Outperform | Upgrade |
| Jul 05, 2023 | Raymond James | - | Outperform | Initialise |
Wave Life Sciences's last stock rating was published by William Blair on Aug 14, 2024. The company Initialise its WVE rating from "null" to "Outperform".
Wave Life Sciences Financial Forecast
Wave Life Sciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $49.21M | $22.11M | $12.93M | $1.24M | $285.00K | - | $1.75M | $1.76M | $36.42M | $2.78M | - | $9.44M | $3.45M | $3.03M | $4.16M | $2.40M | $2.93M | $7.63M | $3.03M | $4.49M | $4.88M |
| Avg Forecast | $28.50M | $15.40M | $12.67M | $12.33M | $19.82M | $17.68M | $19.45M | $25.00M | $19.86M | $23.43M | $7.94M | $32.33M | $7.06M | $8.20M | $3.83M | $3.86M | $15.79M | $10.36M | $9.79M | $10.08M | $9.75M | $12.63M | $6.37M | $5.90M | $5.31M | $5.79M | $15.76M | $9.66M | $4.21M | $4.28M |
| High Forecast | $63.46M | $34.29M | $28.20M | $27.46M | $44.14M | $26.60M | $43.32M | $55.67M | $40.07M | $52.17M | $17.67M | $71.99M | $15.71M | $18.26M | $3.83M | $4.79M | $19.60M | $12.86M | $12.15M | $12.51M | $12.10M | $15.68M | $7.90M | $7.33M | $6.59M | $7.19M | $19.57M | $12.00M | $5.05M | $5.14M |
| Low Forecast | $2.52M | $1.36M | $1.12M | $1.09M | $1.76M | $1.90M | $1.72M | $2.21M | $213.14K | $2.08M | $703.02K | $2.86M | $624.92K | $726.27K | $3.83M | $2.68M | $10.97M | $7.20M | $6.80M | $7.01M | $6.78M | $8.78M | $4.43M | $4.10M | $3.69M | $4.02M | $10.96M | $6.72M | $3.37M | $3.43M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.10% | 2.79% | 0.40% | 0.18% | 0.03% | - | 0.45% | 0.11% | 3.52% | 0.28% | - | 0.97% | 0.27% | 0.48% | 0.70% | 0.45% | 0.51% | 0.48% | 0.31% | 1.07% | 1.14% |
Wave Life Sciences's average Quarter revenue forecast for Dec 23 based on 5 analysts is $19.86M, with a low forecast of $213.14K, and a high forecast of $40.07M. WVE's average Quarter revenue forecast represents a -59.64% decrease compared to the company's last Quarter revenue of $49.21M (Sep 23).
Wave Life Sciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | $4.44M | $-23.47M | $-29.72M | $-43.56M | $-36.89M | - | $-35.61M | $-32.45M | $-3.83M | $-36.33M | $-40.00M | $-27.12M | $-30.59M | $-38.05M | $-45.01M | $-54.34M | $-48.37M | $-39.69M | $-42.04M | $-36.17M | $-34.66M |
| Avg Forecast | $-25.76M | $-13.92M | $-11.45M | $-11.15M | $-17.92M | $-15.98M | $-17.58M | $-22.59M | $-17.95M | $-21.18M | $-7.17M | $-29.22M | $-6.38M | $-7.41M | $-3.46M | $-3.49M | $-14.27M | $-6.25M | $-26.20M | $-24.47M | $-8.81M | $-23.05M | $-30.99M | $-38.26M | $-4.80M | $-43.31M | $-35.76M | $-33.48M | $-33.76M | $-29.82M |
| High Forecast | $-2.28M | $-1.23M | $-1.01M | $-987.25K | $-1.59M | $-1.72M | $-1.56M | $-2.00M | $-192.63K | $-1.88M | $-635.37K | $-2.59M | $-564.79K | $-656.39K | $-3.46M | $-2.42M | $-9.92M | $-5.00M | $-20.96M | $-19.58M | $-6.13M | $-18.44M | $-24.79M | $-30.61M | $-3.33M | $-34.65M | $-28.61M | $-26.78M | $-27.01M | $-23.86M |
| Low Forecast | $-57.35M | $-30.99M | $-25.49M | $-24.82M | $-39.89M | $-24.04M | $-39.15M | $-50.31M | $-36.21M | $-47.15M | $-15.97M | $-65.07M | $-14.20M | $-16.50M | $-3.46M | $-4.33M | $-17.71M | $-7.50M | $-31.44M | $-29.37M | $-10.94M | $-27.66M | $-37.18M | $-45.91M | $-5.95M | $-51.98M | $-42.91M | $-40.18M | $-40.51M | $-35.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.21% | 3.27% | 1.02% | 6.83% | 4.98% | - | 10.21% | 2.27% | 0.61% | 1.39% | 1.63% | 3.08% | 1.33% | 1.23% | 1.18% | 11.33% | 1.12% | 1.11% | 1.26% | 1.07% | 1.16% |
5 analysts predict WVE's average Quarter EBITDA for Dec 23 to be $-17.95M, with a high of $-192.63K and a low of $-36.21M. This is -503.98% lower than Wave Life Sciences's previous annual EBITDA (Sep 23) of $4.44M.
Wave Life Sciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | $7.25M | $-21.10M | $-24.52M | $-43.71M | $-39.11M | - | $-37.53M | $-34.78M | $-6.23M | $-38.77M | $-42.46M | $-28.79M | $-33.10M | $-40.53M | $-47.49M | $-56.77M | $-50.73M | $-41.94M | $-44.20M | $-37.63M | $-35.89M |
| Avg Forecast | $-28.82M | $-39.51M | $-39.51M | $-42.74M | $-36.08M | $-37.19M | $-26.87M | $-24.09M | $-29.36M | $-23.10M | $-42.93M | $-5.18M | $-53.11M | $-64.33M | $-66.14M | $-59.36M | $-57.32M | $-10.16M | $-27.96M | $-25.33M | $-65.50M | $-24.94M | $-33.01M | $-40.37M | $-159.59M | $-45.43M | $-37.79M | $-35.20M | $-35.12M | $-30.88M |
| High Forecast | $5.33M | $7.30M | $7.30M | $7.90M | $6.67M | $-29.22M | $4.97M | $4.45M | $3.09M | $4.27M | $7.94M | $957.77K | $9.82M | $11.89M | $-66.14M | $-35.83M | $-34.60M | $-8.13M | $-22.37M | $-20.27M | $-39.54M | $-19.96M | $-26.41M | $-32.30M | $-96.34M | $-36.34M | $-30.23M | $-28.16M | $-28.10M | $-24.71M |
| Low Forecast | $-74.78M | $-102.50M | $-102.50M | $-110.90M | $-93.62M | $-51.80M | $-69.71M | $-62.51M | $-66.45M | $-59.93M | $-111.38M | $-13.44M | $-137.79M | $-166.92M | $-66.14M | $-77.98M | $-75.30M | $-12.20M | $-33.55M | $-30.40M | $-86.05M | $-29.93M | $-39.61M | $-48.44M | $-209.65M | $-54.51M | $-45.34M | $-42.24M | $-42.15M | $-37.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.31% | 0.49% | 4.73% | 0.82% | 0.61% | - | 0.63% | 0.61% | 0.61% | 1.39% | 1.68% | 0.44% | 1.33% | 1.23% | 1.18% | 0.36% | 1.12% | 1.11% | 1.26% | 1.07% | 1.16% |
Wave Life Sciences's average Quarter net income forecast for Dec 23 is $-29.36M, with a range of $-66.45M to $3.09M. WVE's average Quarter net income forecast represents a -504.85% decrease compared to the company's last Quarter net income of $7.25M (Sep 23).
Wave Life Sciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | $13.13M | $12.27M | $12.23M | $13.72M | $11.61M | - | $12.37M | $12.11M | $12.94M | $10.97M | $10.08M | $9.72M | $9.59M | $10.21M | $13.00M | $13.80M | $12.52M | $11.64M | $10.90M | $9.85M | $8.90M |
| Avg Forecast | $116.93M | $63.19M | $51.97M | $50.60M | $81.34M | $72.56M | $79.82M | $102.57M | $81.50M | $96.14M | $32.57M | $132.66M | $28.95M | $33.64M | $15.73M | $15.83M | $64.77M | $42.49M | $7.91M | $6.01M | $40.01M | $7.23M | $26.12M | $24.22M | $21.78M | $23.75M | $10.49M | $8.68M | $17.28M | $17.57M |
| High Forecast | $260.37M | $140.69M | $115.72M | $112.67M | $181.10M | $109.14M | $177.72M | $228.39M | $164.40M | $214.07M | $72.51M | $295.39M | $64.46M | $74.91M | $15.73M | $19.64M | $80.41M | $52.75M | $9.49M | $7.22M | $49.66M | $8.67M | $32.43M | $30.06M | $27.03M | $29.48M | $12.58M | $10.42M | $20.74M | $21.08M |
| Low Forecast | $10.36M | $5.60M | $4.60M | $4.48M | $7.20M | $7.81M | $7.07M | $9.08M | $874.49K | $8.52M | $2.88M | $11.75M | $2.56M | $2.98M | $15.73M | $11.00M | $45.03M | $29.54M | $6.33M | $4.81M | $27.81M | $5.78M | $18.16M | $16.84M | $15.14M | $16.51M | $8.39M | $6.95M | $13.83M | $14.05M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.14% | 0.38% | 0.09% | 0.47% | 0.35% | - | 0.78% | 0.19% | 0.30% | 1.39% | 1.68% | 0.24% | 1.33% | 0.39% | 0.54% | 0.63% | 0.53% | 1.11% | 1.26% | 0.57% | 0.51% |
Wave Life Sciences's average Quarter SG&A projection for Dec 23 is $81.50M, based on 5 Wall Street analysts, with a range of $874.49K to $164.40M. The forecast indicates a 520.83% rise compared to WVE last annual SG&A of $13.13M (Sep 23).
Wave Life Sciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 9 | 10 | 16 | 9 | 10 | 8 | 8 | 11 | 8 | 18 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | $0.07 | $-0.00 | $-0.24 | $-0.47 | $-0.42 | - | $-0.62 | $-0.61 | $-0.12 | $-0.78 | $-0.86 | $-0.59 | $-0.86 | $-1.15 | $-1.38 | $-1.65 | $-1.48 | $-1.22 | $-1.36 | $-1.28 | $-1.23 |
| Avg Forecast | $-0.22 | $-0.30 | $-0.30 | $-0.33 | $-0.28 | $-0.29 | $-0.21 | $-0.19 | $-0.23 | $-0.18 | $-0.33 | $-0.04 | $-0.41 | $-0.50 | $-0.51 | $-0.54 | $-0.52 | $-0.60 | $-0.62 | $-0.59 | $-0.60 | $-0.69 | $-1.00 | $-1.25 | $-1.46 | $-1.37 | $-1.13 | $-1.19 | $-1.12 | $-0.47 |
| High Forecast | $0.04 | $0.06 | $0.06 | $0.06 | $0.05 | $-0.23 | $0.04 | $0.03 | $0.02 | $0.03 | $0.06 | $0.01 | $0.08 | $0.09 | $-0.51 | $-0.33 | $-0.32 | $-0.36 | $-0.37 | $-0.35 | $-0.36 | $-0.42 | $-0.60 | $-0.75 | $-0.88 | $-0.82 | $-0.68 | $-0.72 | $-0.90 | $-0.38 |
| Low Forecast | $-0.58 | $-0.79 | $-0.79 | $-0.86 | $-0.72 | $-0.40 | $-0.54 | $-0.48 | $-0.51 | $-0.46 | $-0.86 | $-0.10 | $-1.06 | $-1.29 | $-0.51 | $-0.71 | $-0.69 | $-0.79 | $-0.81 | $-0.77 | $-0.78 | $-0.91 | $-1.32 | $-1.64 | $-1.91 | $-1.79 | $-1.48 | $-1.57 | $-1.34 | $-0.57 |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.38% | 0.00% | 6.00% | 1.15% | 0.85% | - | 1.15% | 1.17% | 0.20% | 1.27% | 1.47% | 0.99% | 1.24% | 1.15% | 1.10% | 1.13% | 1.08% | 1.08% | 1.14% | 1.14% | 2.62% |
According to 5 Wall Street analysts, Wave Life Sciences's projected average Quarter EPS for Dec 23 is $-0.23, with a low estimate of $-0.51 and a high estimate of $0.02. This represents a -431.39% decrease compared to WVE previous annual EPS of $0.07 (Sep 23).
Wave Life Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.65 | $3.67 | 464.62% | Buy |
| CTMX | CytomX Therapeutics | $1.20 | $5.77 | 380.83% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| INZY | Inozyme Pharma | $4.98 | $14.00 | 181.12% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| WVE | Wave Life Sciences | $5.13 | $14.00 | 172.90% | Buy |
| ITOS | iTeos Therapeutics | $14.80 | $38.50 | 160.14% | Buy |
| TCRX | TScan Therapeutics | $5.55 | $12.00 | 116.22% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $22.22 | $45.38 | 104.23% | Buy |
| PRQR | ProQR Therapeutics | $1.86 | $3.63 | 95.16% | Buy |
| APLS | Apellis Pharmaceuticals | $41.05 | $75.81 | 84.68% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| MREO | Mereo BioPharma Group | $4.32 | $6.75 | 56.25% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.37 | $3.33 | 40.51% | Buy |
| BPMC | Blueprint Medicines | $86.43 | $101.50 | 17.44% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.78 | $250.16 | 1.37% | Buy |
WVE Forecast FAQ
Is Wave Life Sciences a good buy?
Yes, according to 4 Wall Street analysts, Wave Life Sciences (WVE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of WVE's total ratings.
What is WVE's price target?
Wave Life Sciences (WVE) average price target is $14 with a range of $11 to $17, implying a 172.90% from its last price of $5.13. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Wave Life Sciences stock go up soon?
According to Wall Street analysts' prediction for WVE stock, the company can go up by 172.90% (from the last price of $5.13 to the average price target of $14), up by 231.38% based on the highest stock price target, and up by 114.42% based on the lowest stock price target.
Can Wave Life Sciences stock reach $8?
WVE's average twelve months analyst stock price target of $14 supports the claim that Wave Life Sciences can reach $8 in the near future.
What are Wave Life Sciences's analysts' financial forecasts?
Wave Life Sciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $81.96M (high $169.72M, low $7.6M), average EBITDA is $-74.075M (high $-6.867M, low $-153M), average net income is $-124M (high $-13.132M, low $-278M), average SG&A $336.28M (high $696.36M, low $31.17M), and average EPS is $-0.959 (high $-0.101, low $-2.143). WVE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $68.9M (high $153.41M, low $6.1M), average EBITDA is $-62.27M (high $-5.515M, low $-139M), average net income is $-151M (high $27.84M, low $-391M), average SG&A $282.69M (high $629.45M, low $25.04M), and average EPS is $-1.163 (high $0.215, low $-3.016).
Did the WVE's actual financial results beat the analysts' financial forecasts?
Based on Wave Life Sciences's last annual report (Dec 2023), the company's revenue was $113.3M, beating the average analysts forecast of $83.57M by 35.59%. Apple's EBITDA was $-67.996M, missing the average prediction of $-75.526M by -9.97%. The company's net income was $-57.513M, missing the average estimation of $-101M by -42.81%. Apple's SG&A was $51.29M, missing the average forecast of $342.87M by -85.04%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.776 by -99.94%. In terms of the last quarterly report (Sep 2023), Wave Life Sciences's revenue was $49.21M, beating the average analysts' forecast of $23.43M by 110.03%. The company's EBITDA was $4.44M, missing the average prediction of $-21.177M by -120.98%. Wave Life Sciences's net income was $7.25M, missing the average estimation of $-23.099M by -131.40%. The company's SG&A was $13.13M, missing the average forecast of $96.14M by -86.35%. Lastly, the company's EPS was $0.0684, missing the average prediction of $-0.178 by -138.36%